Table 2 BCMA-targeted CAR-T cell products in clinical trials
Name | Manufacturer | BCMA scFv | Co-stimulatory | Transduction | Extra safety domain |
|---|---|---|---|---|---|
CAR-BCMA | NCI | Murine | CD28 | γ-Retrovirus | No |
Idecabtagene vicleucel; Bb2121 | Bluebird Bio and Celgene | Murine | 4-1BB | Lentivirus | No |
Bb21217 | Bluebird Bio and Celgene | Murine | 4-1BB | Lentivirus | Yes, PI3K inhibitor |
LCAR-B38M | Nanjing Legend/Genscript Biotech | Bi-epitope | 4-1BB | Lentivirus | No |
JNJ-4528 | Janssen Research & Development | Bi-epitope | 4-1BB | Lentivirus | No |
CT053 | CARsgen Therapeutics | Fully human | 4-1BB | Lentivirus | No |
P-BCMA-101 | Poseida Therapeutics | Fully human anti-BCMA CentyrinTM | 4-1BB | PiggyBacâ„¢ (PB) DNA Modification System | No |
CART-BCMA | UPenn/Novartis | Fully human | 4-1BB | Lentivirus | No |
CT103A | Nanjing laso Biotherapeutics | Fully human | 4-1BB | Lentivirus | No |
JCARH125 | Juno Therapeutics | Fully human | 4-1BB | Lentivirus | No |
MCARH171 | MSKCC | Fully human | 4-1BB | γ-Retrovirus | Yes, tEGFR |
BCMA CAR-T | HRAIN Biotech | Fully human | 4-1BB | γ-Retrovirus | Yes, tEGFR |
KITE-585 | Kite, Gilead company | Fully human | CD28 | Lentivirus | No |